Update on GSK litigation

Vectura provides update on GSK litigation

Chippenham, UK - 29 December 2020: Vectura Group plc (LSE: VEC) ("Vectura"), an industry-leading specialist inhalation CDMO, today confirms that GlaxoSmithKline (GSK) has not sought to petition the US Court of Appeals for a re-hearing in our ongoing Ellipta® litigation. Accordingly, the Court of Appeals has issued the Mandate to the United States District Court for the District of Delaware and Vectura expects GSK to make payment of the current award plus interest by late January 2021. The specific amount of the award will be confirmed in due course.

This follows the announcement on 19 November confirming that the US Court of Appeals had denied GSK's motions for a retrial on infringement and for a new trial on damages. GSK may petition the US Supreme Court to review the decision. Such a petition would not impact the timing of GSK making payments on the award.

- Ends-

For more information, please contact:

Vectura Group plc

Elizabeth Knowles - VP Investor Relations +44 (0)7767 160 565

David Ginivan - VP Corporate Communications +44 (0)7471 352 720

Consilium Strategic Communications +44 (0)20 3709 5700

Mary-Jane Elliott / Sue Stuart / David Daley

About Vectura

Vectura is a provider of innovative inhaled drug delivery solutions that enable partners to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapies. 

Vectura has eleven key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz (a division of Novartis AG), Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin KingYork.

For further information, please visit Vectura's website at www.vectura.com

Forward-looking statements

This press release contains forward-looking statements, including statements about the commercialisation of products. Various risks may cause Vectura's actual results to differ materially from those expressed or implied by the forward looking statements, including: commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward looking statements, whether as a result of new information, future events or otherwise.